scholarly journals In vitro and in vivo efficacy of a hydrated sodium calcium aluminosilicate to bind and reduce aflatoxin residues in tissues of broiler chicks fed aflatoxin B1

2013 ◽  
Vol 92 (1) ◽  
pp. 131-137 ◽  
Author(s):  
D.V. Neeff ◽  
D.R. Ledoux ◽  
G.E. Rottinghaus ◽  
A.J. Bermudez ◽  
A. Dakovic ◽  
...  
Keyword(s):  
Aflatoxin B1 ◽  
Broiler Chicks ◽  
In Vivo Efficacy ◽  
Sodium Calcium ◽  
Calcium Aluminosilicate

scholarly journals Efficient Aflatoxin B1 Sequestration by Yeast Cell Wall Extract and Hydrated Sodium Calcium Aluminosilicate Evaluated Using a Multimodal In-Vitro and Ex-Vivo Methodology

Toxins ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 24
Author(s):  
Alexandros Yiannikouris ◽  
Juha Apajalahti ◽  
Hannele Kettunen ◽  
Suvi Ojanperä ◽  
Andrew N. W. Bell ◽  
...  
Keyword(s):  
Cell Wall ◽  
Yeast Cell ◽  
Aflatoxin B1 ◽  
In Vitro Model ◽  
Ex Vivo ◽  
Intestinal Tissue ◽  
Sodium Calcium ◽  
Calcium Aluminosilicate ◽  
Vitro Model

In this work, adsorption of the carcinogenic mycotoxin aflatoxin B1 (AFB1) by two sequestrants—a yeast cell wall-based adsorbent (YCW) and a hydrated sodium calcium aluminosilicate (HSCAS)—was studied across four laboratory models: (1) an in vitro model from a reference method was employed to quantify the sorption capabilities of both sequestrants under buffer conditions at two pH values using liquid chromatography with fluorescence detection (LC-FLD); (2) in a second in vitro model, the influence of the upper gastrointestinal environment on the mycotoxin sorption capacity of the same two sequestrants was studied using a chronic AFB1 level commonly encountered in the field (10 µg/L and in the presence of feed); (3) the third model used a novel ex vivo approach to measure the absorption of 3H-labelled AFB1 in the intestinal tissue and the ability of the sequestrants to offset this process; and (4) a second previously developed ex vivo model readapted to AFB1 was used to measure the transfer of 3H-labelled AFB1 through live intestinal tissue, and the influence of sequestrants on its bioavailability by means of an Ussing chamber system. Despite some sorption effects caused by the feed itself studied in the second model, both in vitro models established that the adsorption capacity of both YCW and HSCAS is promoted at a low acidic pH. Ex vivo Models 3 and 4 showed that the same tested material formed a protective barrier on the epithelial mucosa and that they significantly reduced the transfer of AFB1 through live intestinal tissue. The results indicate that, by reducing the transmembrane transfer rate and reducing over 60% of the concentration of free AFB1, both products are able to significantly limit the bioavailability of AFB1. Moreover, there were limited differences between YCW and HSCAS in their sorption capacities. The inclusion of YCW in the dietary ration could have a positive influence in reducing AFB1′s physiological bioavailability.

Efficacy of b-glucans and manna oligosaccharides (Yeast Cell Wall) and hydrated sodium calcium aluminosilicate (HSCAS) in preventing aflatoxicosis in bovine calves

2017 ◽  
Author(s):  
Omer Naseer ◽  
Jawaria Khan ◽  
Muhammad Khan ◽  
Muhammad Omer ◽  
Muhammad Avais ◽  
...  
Keyword(s):  
Cell Wall ◽  
Yeast Cell ◽  
Hematological Parameters ◽  
Negative Control ◽  
Yeast Cell Wall ◽  
Feed Consumption ◽  
Sodium Calcium ◽  
Calcium Aluminosilicate

The objective of this study was to determine the response of bovine calves against aflatoxin B1 (AFB1) in terms of feed consumption, hematological and serum biochemical parameters and to compare the efficacy of two different mycotoxin adsorbents, in vitro and in vivo. 36 bovine calves were divided into 4 groups. Group A was fed AFB1 added feed with the addition of â-glucans and Mannan oligosaccharides (Yeast Cell Wall), group B was fed AFB1 with hydrated sodium calcium aluminosilicate (HSCAS) and group C was fed AFB1 contaminated feed without addition of mycotoxin binders while group D was kept as negative control. AFB1 was given by gelatinized capsules at a dose rate of 1.0mg/ kg/ animal/ day. Results revealed average daily feed intake (ADFI) of AFB1 treated bovine calves significantly reduced (P less than 0.05) and all hematological parameters i.e; TEC, HGB, TLC, lymphocytes, neutrophils and monocytes, MCHC, HCT and MCH decreased significantly (P less than 0.05). Moreover, serum levels of AST, ALT, Creatinine and BUN were significantly increased (P less than 0.05) in response to AFB1. When compared between groups, YCW significantly (P less than 0.05) improved the feed consumption of bovine calves while HSCAS significantly reduced (P less than 0.05) the AFB1 induced deleterious alterations in hematology and serum biochemistry.

Reduction of Carryover of Aflatoxin from Cow Feed to Milk by Addition of Activated Carbons

1996 ◽  
Vol 59 (5) ◽  
pp. 551-554 ◽  
Author(s):  
FABIO GALVANO ◽  
AMEDEO PIETRI ◽  
TERENZIO BERTUZZI ◽  
GIORGIO FUSCONI ◽  
MARCO GALVANO ◽  
...  
Keyword(s):  
Activated Carbons ◽  
Basal Diet ◽  
Milk Composition ◽  
Aflatoxin M1 ◽  
Sodium Calcium ◽  
Calcium Aluminosilicate ◽  
Pelleted Feed ◽  
Friesian Cows

According to a double-reversal experimental design on 12 late-lactation Friesian cows the effect of two activated carbons (ACs) (CAC1 and CAC2) and a hydrated sodium calcium aluminosilicate (HSCAS) on carryover of aflatoxin B1 (AFB1) from feed to aflatoxin M1 (AFM1) in milk was determined. Cows were fed a basal diet containing AFB1 naturally contaminated corn meal and copra, During week 1 cows were fed diets containing AFB1 alone (11.28 μg of AFB1/kg of feed); in week 2 the diets contained AFB1 plus 2.0% sorbent; and in week 3 the diets again contained AFB1 alone (13.43 μg of AFB1/kg of feed). ACs reduced the analytical content of AFB1 in the pelleted feed by from 40.6% to 73.6%, whereas reduction by HSCAS was 59.2%, The AFM1 concentrations in milk in weeks 1 and 3 were higher than that in week 2, Decreases in the AFM1 excreted in the milk by addition to feed of 2% of the sorbents ranged from 22% to 45%. CAC1 and HSCAS were significantly different from each other in reducing the AFM1concentration in milk (45.3% versus 32.5%); these reductions were significantly higher than that of CAC2 (22.0%). Carryover reduction by addition of CAC1 (50%) was significantly higher than that of HSCAS (36%). Addition of 2% CAC2 did not allow pelleting of feed because of the caking action of this carbon, The lower performance of CAC2 could be related to the unsuccessful pelleting. The addition of ACs did not influence feed intake, milk production, milk composition, or body weight. Our results suggest that ACs, high-affinity sorbents for AFB1 in vitro, are efficacious in reducing AFB1 carryover from cow feed to milk. Further in vivo investigations should establish lower amounts of ACs which can be efficacious.

scholarly journals Saccharomyces cerevisiae Cell Wall-Based Adsorbent Reduces Aflatoxin B1 Absorption in Rats

Toxins ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 209
Author(s):  
Alexandros Yiannikouris ◽  
Juha Apajalahti ◽  
Osmo Siikanen ◽  
Gerald Patrick Dillon ◽  
Colm Anthony Moran
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Cell Wall ◽  
Aflatoxin B1 ◽  
Control Diet ◽  
The Body ◽  
Pharmacokinetic Analysis ◽  
Negative Effects ◽  
Calcium Aluminosilicate

Mycotoxins are naturally occurring toxins that can affect livestock health and performance upon consumption of contaminated feedstuffs. To mitigate the negative effects of mycotoxins, sequestering agents, adsorbents, or binders can be included to feed to interact with toxins, aiding their passage through the gastrointestinal tract (GI) and reducing their bioavailability. The parietal cell wall components of Saccharomyces cerevisiae have been found to interact in vitro with mycotoxins, such as, but not limited to, aflatoxin B1 (AFB1), and to improve animal performance when added to contaminated diets in vivo. The present study aimed to examine the pharmacokinetics of the absorption of radiolabeled AFB1 in rats in the presence of a yeast cell wall-based adsorbent (YCW) compared with that in the presence of the clay-based binder hydrated sodium calcium aluminosilicate (HSCAS). The results of the initial pharmacokinetic analysis showed that the absorption process across the GI tract was relatively slow, occurring over a matter of hours rather than minutes. The inclusion of mycotoxin binders increased the recovery of radiolabeled AFB1 in the small intestine, cecum, and colon at 5 and 10 h, revealing that they prevented AFB1 absorption compared with a control diet. Additionally, the accumulation of radiolabeled AFB1 was more significant in the blood plasma, kidney, and liver of animals fed the control diet, again showing the ability of the binders to reduce the assimilation of AFB1 into the body. The results showed the potential of YCW in reducing the absorption of AFB1 in vivo, and in protecting against the damaging effects of AFB1 contamination.

scholarly journals Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Pierre Santucci ◽  
Daniel J. Greenwood ◽  
Antony Fearns ◽  
Kai Chen ◽  
Haibo Jiang ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Host Cell ◽  
Combination Chemotherapy ◽  
In Vitro Activity ◽  
In Vivo Efficacy ◽  
Human Macrophages ◽  
Ion Microscopy ◽  
Intracellular Localisation

AbstractTo be effective, chemotherapy against tuberculosis (TB) must kill the intracellular population of the pathogen, Mycobacterium tuberculosis. However, how host cell microenvironments affect antibiotic accumulation and efficacy remains unclear. Here, we use correlative light, electron, and ion microscopy to investigate how various microenvironments within human macrophages affect the activity of pyrazinamide (PZA), a key antibiotic against TB. We show that PZA accumulates heterogeneously among individual bacteria in multiple host cell environments. Crucially, PZA accumulation and efficacy is maximal within acidified phagosomes. Bedaquiline, another antibiotic commonly used in combined TB therapy, enhances PZA accumulation via a host cell-mediated mechanism. Thus, intracellular localisation and specific microenvironments affect PZA accumulation and efficacy. Our results may explain the potent in vivo efficacy of PZA, compared to its modest in vitro activity, and its critical contribution to TB combination chemotherapy.

scholarly journals P074 In vitro and in vivo efficacy of linezolid on Treponema pallidum, the syphilis agent

2021 ◽  
Author(s):  
L Giacani ◽  
A Haynes ◽  
M Vall Mayans ◽  
M Ubals Cazorla ◽  
C Nieto ◽  
...  
Keyword(s):  
Treponema Pallidum ◽  
In Vivo Efficacy

scholarly journals Efficacy of a novel lantibiotic, CMB001, against MRSA

2021 ◽  
Author(s):  
Jerzy Karczewski ◽  
Christine M Brown ◽  
Yukari Maezato ◽  
Stephen P Krasucki ◽  
Stephen J Streatfield
Keyword(s):  
Antibacterial Activity ◽  
Pharmacokinetic Analysis ◽  
Maximum Tolerable Dose ◽  
In Vivo Efficacy ◽  
Clostridioides Difficile ◽  
Alternative Treatment Option ◽  
Significant Damage ◽  
Tolerable Dose

Abstract Objectives To evaluate the efficacy of a novel lantibiotic, CMB001, against MRSA biofilms in vitro and in an in vivo experimental model of bacterial infection. Methods Antibacterial activity of CMB001 was measured in vitro after its exposure to whole blood or to platelet-poor plasma. In vitro efficacy of CMB001 against a Staphylococcus aureus biofilm was studied using scanning electron microscopy. The maximum tolerable dose in mice was determined and a preliminary pharmacokinetic analysis for CMB001 was performed in mice. In vivo efficacy was evaluated in a neutropenic mouse thigh model of infection. Results CMB001 maintained its antibacterial activity in the presence of blood or plasma for up to 24 h at 37°C. CMB001 efficiently killed S. aureus within the biofilm by causing significant damage to the bacterial cell wall. The maximum tolerable dose in mice was established to be 10 mg/kg and could be increased to 30 mg/kg in mice pretreated with antihistamines. In neutropenic mice infected with MRSA, treatment with CMB001 reduced the bacterial burden with an efficacy equivalent to that of vancomycin. Conclusions CMB001 offers potential as an alternative treatment option to combat MRSA. It will be of interest to evaluate the in vivo efficacy of CMB001 against infections caused by other pathogens, including Clostridioides difficile and Acinetobacter baumannii, and to expand its pharmacokinetic/pharmacodynamic parameters and safety profile.

Sign in / Sign up

Export Citation Format

Share Document